CAR T-Cell Therapy for Solid Tumors Market Size, Share & Growth Forecast 2026–2035
According to Rohan Patil, who specializes in healthcare research, pharmaceuticals, and therapeutic areas with 5+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the CAR T-cell therapy for solid tumors market. The CAR T-cell therapy for solid tumors market size was estimated at USD 1.42 billion in 2025 and is predicted to increase from USD 1.83 billion in 2026 to approximately USD 17.98 billion by 2035, expanding at a CAGR of 28.9% from 2026 to 2035. His analysis highlights vast growth in the patient population and the need for durable treatments, with breakthroughs in gene editing & next-generation CAR design. The research also examines the competitive strategies of key industry participants, including CARsgen Therapeutics, Autolus Therapeutics, Novartis, Adaptimmune, Gilead Sciences (Kite), & Bristol Myers Squibb (BMS), shaping the future of CAR T-cell therapy for solid tumors in the global market.
Last Updated : 08 July 2026
Category: Therapeutic Area
Insight Code: 6999
Format: PDF / PPT / Excel